农业百科

世界农化网中文网报道：巴西一家农业咨询机构最新预测显示，2026/27作物季，巴西农业投入品行业市场规模有望回升至3000亿雷亚尔（约合550亿美元），同比增长8%，结束了过去四年的行业调整期。这一数字已接近2022/23季创下的3140亿雷亚尔历史峰值。该机构分析师指出，当前复苏的市场条件与当年不同——供应链库存已恢复至更平衡的水平，制造商和经销商能够在更健康的定价结构下运营。

世界农化网中文网报道：近日，江西众和集团旗下公司江西众和生物科技有限公司成功获得公司首张巴西登记证——丁噻隆（Tebuthiuron）98% TC。

Fundación Veg and its certification arm V-Label Latam will be present at Alimentec, the biennial food and beverage trade fair held at Corferias in Bogotá, Colombia, from 9 to 12 June 2026. The two organizations will share a stand in Hall 6, Level 1, Booth 508, where they plan to meet food and beverage companies interested in vegan certification and related market opportunities.

Under the agreement, Nurix will receive US$700m upfront and could earn development, regulatory and sales milestones bringing the total potential value to US$2.3bn. The partners will share development costs, with Roche funding 60% and Nurix 40%. In the US, the companies will split profits and losses equally and co-commercialise the drug, while Roche will take responsibility for commercialisation outside the US, paying Nurix tiered royalties in the low- to high-teens. The transaction is expected to close in Q3/2026, subject to customary conditions.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Tanmiah Food Company (“Tanmiah”), through its subsidiary Agricultural Development Company (ADC), a leading provider of fresh and frozen poultry and value-added products, proudly announces a double victory at the prestigious Product of the Year Gulf (POY) 2026 awards.

五月中下旬，罕见极端暴雨席卷黔东南、黔南全域，连日暴雨致使河水暴涨，山洪、泥石流侵袭村镇，多地农田大面积被淹。

Revo Foods is expanding its mycelium portfolio beyond seafood and standalone proteins, launching a new line of whole-cut chicken fillets.

More acutely than most companies, Abivax (Euronext Paris and Nasdaq: ABVX) felt firsthand the ups and downs of the proverbial stock market roller coaster this past week as investor fears over safety signals associated with the French biotech’s late-stage ulcerative colitis (UC) drug candidate briefly overshadowed its positive Phase III clinical results.